A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.
Open Access
- 1 April 1995
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 181 (4) , 1527-1537
- https://doi.org/10.1084/jem.181.4.1527
Abstract
Leishmania braziliensis causes cutaneous and mucosal leishmaniasis in humans. Most patients with cutaneous leishmaniasis heal spontaneously and may therefore have developed protective immunity. There appears to be a mixed cytokine profile associated with active cutaneous or mucosal disease, and a dominant T helper (Th)1-type response associated with healing. Leishmanial antigens that elicit these potent proliferative and cytokine responses from peripheral blood mononuclear cells (PBMC) are now being identified. Herein, we report on the cloning and expression of a L. braziliensis gene homologous to the eukaryotic ribosomal protein eIF4A (LeIF) and patient PBMC responses to rLeIF. Patients with mucosal and self-healing cutaneous disease had significantly higher proliferative responses than those with cutaneous lesions. Whereas the parasite lysate stimulated patient PBMC to produce a mixed Th1/Th2-type cytokine profile, LeIF stimulated the production of interferon gamma (IFN-gamma), interleukin 2 (IL-2), and tumor necrosis factor alpha but not IL-4 or IL-10. Recombinant LeIF (rLeIF) downregulated both IL-10 mRNA in the "resting" PBMC of leishmaniasis patients and LPS-induced IL-10 production by patient PBMC. rLeIF also stimulated the production of IL-12 in cultured PBMC from both patients and uninfected individuals. The production of IFN-gamma by patient PBMC stimulated with either rLeIF or parasite lysate was IL-12 dependent, whereas anti-IFN-gamma monoclonal antibody only partially blocked the LeIF-induced production of IL-12. In vitro production of both IFN-gamma and IL-12 was abrogated by exogenous human recombinant IL-10. Therefore, we have identified a recombinant leishmanial antigen that elicits IL-12 production and Th1-type responses in patients as well as IL-12 production in normal human PBMC.Keywords
This publication has 45 references indexed in Scilit:
- Tumor necrosis factor‐α in combination with interferon‐γ, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotesEuropean Journal of Immunology, 1990
- Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.The Journal of Experimental Medicine, 1990
- Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis.The Journal of Experimental Medicine, 1989
- Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.The Journal of Experimental Medicine, 1989
- Macrophage activation by interferon‐γ from host‐protective T cells is inhibited by interleukin (IL) 3 and IL 4 produced by disease‐promoting T cells in leishmaniasisEuropean Journal of Immunology, 1989
- Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.The Journal of Immunology, 1989
- Birth of the D-E-A-D boxNature, 1989
- Sequence of the genesTIF1andTIF2fromSaccharomyces cerevisiaecoding for a translation initiation factorNucleic Acids Research, 1988
- Spontaneous healing of cutaneous Leishmania braziliensis braziliensis ulcersTransactions of the Royal Society of Tropical Medicine and Hygiene, 1987
- Epidemiology of American Cutaneous Leishmaniasis Due to Leishmania braziliensis brasiliensisThe Journal of Infectious Diseases, 1987